Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Branford, Susan; Rudzki, Zbigniew; Walsh, Sonya; Parkinson, Ian; Grigg, Andrew; Szer, Jeffrey; Taylor, Kerry; Herrmann, Richard; Seymour, John F.; Arthur, Chris; Joske, David; Lynch, Kevin; Hughes, Toby

doi:10.1182/blood-2002-09-2896

Cited by 702 publications

(576 citation statements)

References 28 publications

Supporting

Mentioning

512

Contrasting

Unclassified

Order By: Relevance

“…23 The most common cause of secondary imatinib resistance is point mutations in BCR-ABL that prevent effective binding of imatinib but may retain kinase activity. [35][36][37][38][39] These mutations are clustered primarily within the kinase domain of BCR-ABL (ABL exons 4-10). 40 They exhibit differential relative resistance to imatinib in vitro.…”

Section: Imatinib Nilotinib Dasatinibmentioning

confidence: 99%

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase

Kantarjian

Cortés

Rosée

et al. 2010

Cancer

View full text Add to dashboard Cite

Identification of BCR‐ABL as the defining leukemogenic event in chronic myelogenous leukemia (CML) revolutionized the treatment of the disease. Imatinib, a potent BCR‐ABL inhibitor, is the standard of care for the first‐line treatment of patients with chronic‐phase CML because of its high long‐term response rates and favorable tolerability profile compared with previous standard therapies. However, resistance to imatinib develops in 2% to 4% of patients annually. For patients with acquired cytogenetic resistance to standard‐dose imatinib (400 mg daily), imatinib dose escalation (600‐800 mg daily) is an excellent first option for managing patients and achieving cytogenetic responses. However, for patients with primary resistance to imatinib, hematologic disease recurrence, or emergent BCR‐ABL kinase domain mutations, imatinib dose escalation may not be sufficient to control the disease. For these patients, the potent second‐generation tyrosine kinase inhibitors dasatinib and nilotinib are available. Both agents provide effective therapeutic options for patients with imatinib resistance or intolerance. For the current overview, the authors reviewed the data supporting the use of both dasatinib and nilotinib in imatinib‐resistant or imatinib‐intolerant patients, and they have highlighted the future of CML therapy. Overall, the article is intended to offer physicians a comprehensive review of the current literature and to provide data supporting various treatment options for patients with CML throughout the course of imatinib therapy and beyond. Cancer 2010. © 2010 American Cancer Society.

show abstract

Section: Imatinib Nilotinib Dasatinibmentioning

confidence: 99%

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase

Kantarjian

Cortés

Rosée

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

“…In 70 -80% of these cases, acquired resistance is caused by point mutations in the ABL kinase domain (Gorre et al, 2001). So far, about 40 different point mutations have been discovered, each of which is sufficient to cause resistance to imatinib (Branford et al, 2003a). Of those patients who start imatinib in the early chronic, late chronic and accelerated phase, respectively, 12, 32 and 62% develop detectable resistance within 2 years of treatment (Branford et al, 2003b).…”

Section: Dynamics Of CMLmentioning

confidence: 99%

Mathematical models of targeted cancer therapy

Abbott

Michor

2006

Br J Cancer

View full text Add to dashboard Cite

Improved understanding of the molecular underpinnings of cancer initiation and progression has led to the development of targeted cancer therapies. The importance of these new methods of cancer treatment necessitates further research into the dynamic interactions between cancer cells and therapeutic agents, as well as a means of analysing their relationship quantitatively. The present review outlines the application of mathematical modelling to the dynamics of targeted cancer therapy, focusing particular attention on chronic myeloid leukaemia and its treatment with imatinib (Glivec).

show abstract

“…This mechanism has perhaps been most widely studied and appears to be the most common mechanism of resistance in clinical practice (Gorre et al, 2001;Branford et al, 2002;Hochhaus et al, 2002;Shah et al, 2002;Branford et al, 2003).…”

Section: Imatinib Resistancementioning

confidence: 99%

Cancer treatment with kinase inhibitors: what have we learnt from imatinib?

Ross

Hughes

2004

Br J Cancer

View full text Add to dashboard Cite

Over the past few years, a number of anticancer drugs have been developed that specifically target kinases known to be oncogenic. The leading drug in this area is imatinib mesylate, which targets ABL, KIT and PDGFR. It has been remarkably effective in the treatment of chronic myeloid leukaemia, although resistance remains a significant problem. From the imatinib experience in this setting, we present some principles of kinase inhibition that may have more general applicability in targeted anticancer therapy. It is clear that the identification of appropriate targets (activated kinases) and monitoring levels of response (to recognise emerging resistance) are essential to optimise clinical management.

show abstract

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Cited by 702 publications

References 28 publications

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase

Mathematical models of targeted cancer therapy

Cancer treatment with kinase inhibitors: what have we learnt from imatinib?

Contact Info

Product

Resources

About